There is first evidence from preclinical and clinical studies for the efficacy of the
selective GABA-B receptor agonist baclofen in the treatment of alcohol dependence. The aim of
this trial is to evaluate the efficacy and safety of individually titrated high-dose baclofen
for relapse prevention in alcohol-dependent patients.